At #ClimateWeekNYC, we shared how partnership is critical for healthier people, health systems and the planet. Highlights included: our $100m Young Health Programme commitment, a new tool that models the environmental impact of care pathways and the European Network on Climate and Health Education reaching 6,000 medical students. Thanks to colleagues, partners and young leaders who made this progress possible.

We’re investing more than $100m in our Young Health Programme 2010 to 2030, in partnership with @UNICEF and 60 NGO partners. By 2030, the programme aims to reach 10m more young people in underserved communities and train 800,000 youth advocates. Learn more: learn.az/6016BGdXUg #YoungHealthProgramme

Patient care delivery accounts for around 40% of emissions from the healthcare sector. Today we're launching CARESA, a free tool that helps health systems estimate the environmental footprint of care pathways and explore opportunities for more sustainable care🌍 🔗learn.az/6013BGjHml

Named #5 in TIME’s World’s Best Companies and ranked #1 in our industry 🌍 Behind this recognition: 96,000+ colleagues, partners and suppliers working together for people, society and the planet. learn.az/6013BGKaxt #WhatScienceCanDo #TIME #WorldsBestCompanies

32 young leaders from 24 countries. One shared goal: better health. Meet our 2026 Young Health Programme Impact Fellows and Scholars taking action on health equity, health systems resilience and climate and nature. With @OneYoungWorld and @YouthAssembly. #YoungHealthProgramme

Named among @TIME World's Most Sustainable Companies for the third consecutive year. Sustainability is embedded in our strategy and how we operate — helping us build a more resilient, efficient business as we deliver life-changing medicines and support a healthier future for people and the planet. Learn more: learn.az/6013BDj2gd #WhatScienceCanDo

We focus on advancing research and understanding of generalised myasthenia gravis (MG), guided by those affected and aiming to improve care and outcomes. #MGAwarenessMonth #MyastheniaGravis #RareDiseases

Today we rang the opening bell at @NYSE to mark our recent share listing and harmonised trading across New York, London and Stockholm. This moment reflects the science, innovation and teamwork helping us turn bold ideas into life-changing medicines. #AZN #WhatScienceCanDo

Named one of @FinancialTimes Europe’s Climate Leaders for the 6th consecutive year. Our $1bn Ambition Zero Carbon programme has delivered: ↘️88% cut in Scope 1 & 2 emissions 🔋81% EV fleet 💡80%+ supplier spend with SBT partners. Read more: ft.com/content/1d4be2a3-e986… #WhatScienceCanDo

This Eosinophilic Diseases Awareness Month, we're calling for earlier diagnosis, better care and continued progress for people living with eosinophilic diseases such as eosinophilic esophagitis (EoE). #EAM2026 #WorldEOEDay

For investor audiences and business/financial media only 📈 We delivered strong growth in Q1 2026 with Total Revenue above $15 billion, demonstrating our consistent commercial execution as we transform patient care. Learn more: astrazeneca.com/media-centre… #AZN #FinancialResults

Receiving a rare disease diagnosis often takes five years and involves multiple doctors, specialists, and misdiagnoses. Improving the diagnostic process can help shorten this journey for the rare disease community. #RareDisease

We highlight the neuromyelitis optica spectrum disorder (NMOSD) community and share insights to support understanding and collaboration in healthcare. #NMOAwarenessMonth #NMOSD #RareDisease

Rare Disease Day (28 Feb) is a global call to act for more than 400 million people living with rare conditions and their caregivers. Learn how we listen to and partner with the rare disease community to speed up access to diagnosis and equitable care: learn.az/6017hmwt9

More than 10,000 rare diseases affect over 400 million people worldwide. Fewer than 10% of these conditions have an approved treatment. Developing and delivering innovative therapies is essential to reach more people in need. #RareDisease